Overview

Relative Bioavailability For Palbociclib Formulations

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This study is to assess the relative bioavailability of palbociclib hard gelatin capsule formulation (API 41 micrometer and dissolution Level 1) and palbociclib hard gelatin capsule formulation (API 16 micrometer and dissolution Level 2) compared to the palbociclib hard gelatin capsule formulation (API 16 micrometer and dissolution Level 1) after single 125 mg oral doses under fed conditions in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Palbociclib